Want to see ELVN full AI Analyst Report?

Enliven Therapeutics (ELVN) Price & Analysis

345 Followers

ELVN Stock Chart & Stats

$48.11

$0.01(0.04%)

At close: Jan 08 4:00 PM EST

$48.11

$0.01(0.04%)

Day’s Range― - ―

52-Week Range$14.79 - $54.10

Previous CloseN/A

Volume37.78K

Average Volume (3M)1.93M

Market Cap

$3.80B

Enterprise Value$2.60B

Total Cash (Recent Filing)$452.40M

Total Debt (Recent Filing)$302.00K

Price to Earnings (P/E)―

Beta0.97

Next Earnings

Aug 19, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.64

Shares Outstanding71,438,280

10 Day Avg. Volume903,620

30 Day Avg. Volume1,931,443

Financial Highlights & Ratios

PEG Ratio2.65

Price to Book (P/B)1.90

Price to Sales (P/S)0.00

P/FCF Ratio-12.38

Enterprise Value/Market Cap0.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-43.34K

Enterprise Value/Ebitda-26.38

Forecast

1Y Price Target

$65.44

Price Target Upside36.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)-1.73

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthNear-zero debt and a materially stronger equity base provide durable financial flexibility to fund multi-year clinical programs without immediate refinancing pressure. This lowers solvency risk, supports sustained R&D investment, and improves the company’s ability to execute pivotal trials through 2–3 year development timelines.

Positive Phase 1 ELVN-001 DataRobust early efficacy and a favorable safety/selectivity profile, coupled with FDA alignment on Phase 3 dose and enrollment strategy, materially de-risks the program. This structural progress improves the probability that ELVN-001 can advance to a registrational pathway and, if successful, become a commercial product in CML.

Large Upsized Equity OfferingAn immediate, sizeable capital raise materially extends the cash runway to fund pivotal studies and development milestones. Access to deep capital markets via a successful upsized deal reduces short-term financing risk and allows the company to advance multiple programs without immediate program cuts or partner dependence.

Bears Say

Pre-Revenue StatusBeing pre-revenue means long-term value creation depends entirely on clinical and regulatory success; widening operating losses (EBIT moved from about -$25M in 2021 to about -$120M in 2025) increase the magnitude of eventual commercialization risk and magnify consequences if trials fail or face delays.

Sustained Cash BurnConsistent multi-year negative free cash flow at material rates creates ongoing reliance on external capital. Persistent cash burn elevates dilution risk, constrains optionality for pursuing additional indications, and could force program prioritization if future financing conditions tighten or trial costs exceed projections.

Authorized Shares & Dilution RiskExpanding authorized shares and executing large equity issuances increase structural dilution risk for existing holders. While the moves boost financing flexibility, repeated reliance on equity to fund operations can erode per-share economics and investor returns unless offset by successful clinical outcomes and eventual product revenues.

Enliven Therapeutics News

Enliven price target raised to $67 from $59 at Goldman Sachs

Goldman Sachs analyst Salveen Richter raised the firm’s price target on Enliven (ELVN) to $67 from $59 and...

28m ago

ELVN

Enliven price target raised to $65 from $56 at H.C. Wainwright

H.C. Wainwright analyst Robert Burns raised the firm’s price target on Enliven (ELVN) to $65 from $56 and...

12d ago

ELVN

Enliven price target raised to $80 from $60 at Stifel

Stifel raised the firm’s price target on Enliven (ELVN) to $80 from $60 and keeps a Buy rating...

20d ago

ELVN

Enliven price target raised to $70 from $45 at JonesResearch

JonesResearch raised the firm’s price target on Enliven (ELVN) to $70 from $45 and keeps a Buy rating...

22d ago

ELVN

Enliven Therapeutics Prices Upsized Public Equity Offering

The latest update is out from Enliven Therapeutics ( ($ELVN) ). On June 11, 2026, Enliven Therapeutics priced...

1M ago

ELVN

Why Is Enliven Therapeutics Stock (ELVN) Up Today?

Enliven Therapeutics stock was up on news of an upsized public offering. ...

1M ago

ELVN

Enliven rises 9.9%

Enliven (ELVN) is up 9.9%, or $4.01 to $44.37. Published first on TheFly – the ultimate source for...

1M ago

ELVN

Enliven 8.9M share Spot Secondary priced at $37.50

The deal size was increased to $400M in common stock from $250M in common stock. Jefferies, Goldman Sachs,...

1M ago

ELVN

Enliven announces $250M common stock offering

Enliven (ELVN) Therapeutics announced that it has commenced an underwritten public offering of $250M of shares of its...

1M ago

ELVN

Midday Fly By: Oracle slides, SpaceX on deck for public debut

The major averages slightly rebounded from one-month lows on Thursday with support from the tech sector even though...

1M ago

Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential

JonesTrading analyst Boris Peaker has reiterated their bullish stance on ELVN stock, giving a Buy rating on June...

1M ago

ELVN

Enliven rises 14.8%

Enliven (ELVN) is up 14.8%, or $5.48 to $42.48. Published first on TheFly – the ultimate source for...

1M ago

ELVN

Enliven advances ELVN-001 with positive Phase 1 data

The latest announcement is out from Enliven Therapeutics ( ($ELVN) ). On June 11, 2026, Enliven reported updated...

1M ago

ELVN

Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial

08:15 EDT Enliven (ELVN) up 15% to $42.50 after positive data from Phase 1 ENABLE trial Published first...

1M ago

ELVN

ELVN FAQ

What was Enliven Therapeutics, Inc.’s price range in the past 12 months?

Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $54.10 in the past 12 months.

What is Enliven Therapeutics, Inc.’s market cap?

Enliven Therapeutics, Inc.’s market cap is $3.80B.

When is Enliven Therapeutics, Inc.’s upcoming earnings report date?

Enliven Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 29 days.

How were Enliven Therapeutics, Inc.’s earnings last quarter?

Enliven Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.064.

Is Enliven Therapeutics, Inc. overvalued?

According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Enliven Therapeutics, Inc. pay dividends?

Enliven Therapeutics, Inc. does not currently pay dividends.

What is Enliven Therapeutics, Inc.’s EPS estimate?

Enliven Therapeutics, Inc.’s EPS estimate is -0.39.

How many shares outstanding does Enliven Therapeutics, Inc. have?

Enliven Therapeutics, Inc. has 71,438,280 shares outstanding.

What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?

Enliven Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went up 1.142%.

Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?

Currently, no hedge funds are holding shares in ELVN

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Enliven Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

53.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Enliven Therapeutics (ELVN) Earnings & Revenues

Historic Earnings Reports

ELVN Stock 12 Month Forecast

Average Price Target

$65.44

▲(36.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","81":"$81","30.75":"$30.8","47.5":"$47.5","64.25":"$64.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":80,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$80.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65.44444444444444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$65.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$55.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,30.75,47.5,64.25,81],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,51.16307692307692,53.566153846153846,55.96923076923077,58.37230769230769,60.77538461538462,63.178461538461534,65.58153846153846,67.98461538461538,70.3876923076923,72.79076923076923,75.19384615384615,77.59692307692308,{"y":80,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,50.0434188034188,51.32683760683761,52.61025641025641,53.89367521367521,55.177094017094014,56.46051282051282,57.74393162393162,59.02735042735043,60.310769230769225,61.594188034188036,62.877606837606834,64.16102564102565,{"y":65.44444444444444,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,48.76,49.239999999999995,49.72,50.199999999999996,50.68,51.16,51.64,52.12,52.6,53.08,53.56,54.04,54.519999999999996,{"y":55,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.73,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.89,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.82,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.42,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.85,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.7,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >